Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma.

Schmidts A, Ormhøj M, Choi BD, Taylor AO, Bouffard AA, Scarfò I, Larson RC, Frigault MJ, Gallagher K, Castano AP, Riley LS, Cabral ML, Boroughs AC, Velasco Cárdenas RM, Schamel W, Zhou J, Mackay S, Tai YT, Anderson KC, Maus MV.

Blood Adv. 2019 Nov 12;3(21):3248-3260. doi: 10.1182/bloodadvances.2019000703.

PMID:
31698455
2.

Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphoma.

Abramson JS, Irwin KE, Frigault MJ, Dietrich J, McGree B, Jordan JT, Yee AJ, Chen YB, Raje NS, Barnes JA, Davis B.

Cancer. 2019 Nov 1;125(21):3692-3698. doi: 10.1002/cncr.32411. Epub 2019 Sep 10. No abstract available.

PMID:
31503324
3.

Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19.

Ormhøj M, Scarfò I, Cabral ML, Bailey SR, Lorrey SJ, Bouffard AA, Castano AP, Larson RC, Riley LS, Schmidts A, Choi BD, Andersen RS, Cédile O, Nyvold CG, Christensen JH, Gjerstorff MF, Ditzel HJ, Weinstock DM, Barington T, Frigault MJ, Maus MV.

Clin Cancer Res. 2019 Aug 22. doi: 10.1158/1078-0432.CCR-19-1337. [Epub ahead of print]

PMID:
31439577
4.

CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity.

Choi BD, Yu X, Castano AP, Bouffard AA, Schmidts A, Larson RC, Bailey SR, Boroughs AC, Frigault MJ, Leick MB, Scarfò I, Cetrulo CL, Demehri S, Nahed BV, Cahill DP, Wakimoto H, Curry WT, Carter BS, Maus MV.

Nat Biotechnol. 2019 Sep;37(9):1049-1058. doi: 10.1038/s41587-019-0192-1. Epub 2019 Jul 22.

PMID:
31332324
5.

Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma.

Frigault MJ, Dietrich J, Martinez-Lage M, Leick M, Choi BD, DeFilipp Z, Chen YB, Abramson J, Crombie J, Armand P, Nayak L, Panzini C, Riley LS, Gallagher K, Maus MV.

Blood. 2019 Sep 12;134(11):860-866. doi: 10.1182/blood.2019001694. Epub 2019 Jul 18.

PMID:
31320380
6.

CAR-Based Approaches to Cutaneous T-Cell Lymphoma.

Scarfò I, Frigault MJ, Maus MV.

Front Oncol. 2019 Apr 16;9:259. doi: 10.3389/fonc.2019.00259. eCollection 2019. Review.

7.

Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells.

Karschnia P, Jordan JT, Forst DA, Arrillaga-Romany IC, Batchelor TT, Baehring JM, Clement NF, Gonzalez Castro LN, Herlopian A, Maus MV, Schwaiblmair MH, Soumerai JD, Takvorian RW, Hochberg EP, Barnes JA, Abramson JS, Frigault MJ, Dietrich J.

Blood. 2019 May 16;133(20):2212-2221. doi: 10.1182/blood-2018-12-893396. Epub 2019 Feb 26.

PMID:
30808634
8.

Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas.

Scarfò I, Ormhøj M, Frigault MJ, Castano AP, Lorrey S, Bouffard AA, van Scoyk A, Rodig SJ, Shay AJ, Aster JC, Preffer FI, Weinstock DM, Maus MV.

Blood. 2018 Oct 4;132(14):1495-1506. doi: 10.1182/blood-2018-04-842708. Epub 2018 Aug 8. Erratum in: Blood. 2018 Dec 6;132(23):2527.

9.

CARs in the Lead Against Multiple Myeloma.

Ormhøj M, Bedoya F, Frigault MJ, Maus MV.

Curr Hematol Malig Rep. 2017 Apr;12(2):119-125. doi: 10.1007/s11899-017-0373-2. Review.

10.

The Flipside of the Power of Engineered T Cells: Observed and Potential Toxicities of Genetically Modified T Cells as Therapy.

Bedoya F, Frigault MJ, Maus MV.

Mol Ther. 2017 Feb 1;25(2):314-320. doi: 10.1016/j.ymthe.2016.11.011. Review.

11.

Chimeric antigen receptor-modified T cells strike back.

Frigault MJ, Maus MV.

Int Immunol. 2016 Jul;28(7):355-63. doi: 10.1093/intimm/dxw018. Epub 2016 Mar 28. Review.

12.

Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells.

Frigault MJ, Lee J, Basil MC, Carpenito C, Motohashi S, Scholler J, Kawalekar OU, Guedan S, McGettigan SE, Posey AD Jr, Ang S, Cooper LJ, Platt JM, Johnson FB, Paulos CM, Zhao Y, Kalos M, Milone MC, June CH.

Cancer Immunol Res. 2015 Apr;3(4):356-67. doi: 10.1158/2326-6066.CIR-14-0186. Epub 2015 Jan 19.

13.

ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.

Guedan S, Chen X, Madar A, Carpenito C, McGettigan SE, Frigault MJ, Lee J, Posey AD Jr, Scholler J, Scholler N, Bonneau R, June CH.

Blood. 2014 Aug 14;124(7):1070-80. doi: 10.1182/blood-2013-10-535245. Epub 2014 Jul 1.

14.

Predicting cytokine storms: it's about density.

Frigault MJ, June CH.

Blood. 2011 Dec 22;118(26):6724-6. doi: 10.1182/blood-2011-10-382598. No abstract available.

PMID:
22194391
15.

Defining the role of syndecan-4 in mechanotransduction using surface-modification approaches.

Bellin RM, Kubicek JD, Frigault MJ, Kamien AJ, Steward RL Jr, Barnes HM, Digiacomo MB, Duncan LJ, Edgerly CK, Morse EM, Park CY, Fredberg JJ, Cheng CM, LeDuc PR.

Proc Natl Acad Sci U S A. 2009 Dec 29;106(52):22102-7. doi: 10.1073/pnas.0902639106. Epub 2009 Dec 22.

Supplemental Content

Loading ...
Support Center